Markets

GW Pharmaceuticals PLC (GWPH) Outpaces Stock Market Gains: What You Should Know

GW Pharmaceuticals PLC (GWPH) closed at $129.65 in the latest trading session, marking a +1.73% move from the prior day. This change outpaced the S&P 500's 0.19% gain on the day. Meanwhile, the Dow lost 0.11%, and the Nasdaq, a tech-heavy index, added 0.81%.

Heading into today, shares of the company had gained 4.54% over the past month, outpacing the Medical sector's loss of 1.57% and the S&P 500's gain of 0.56% in that time.

GWPH will be looking to display strength as it nears its next earnings release, which is expected to be November 5, 2019. On that day, GWPH is projected to report earnings of -$0.85 per share, which would represent year-over-year growth of 69.2%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $88.26 million, up 3547.11% from the year-ago period.

Investors might also notice recent changes to analyst estimates for GWPH. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1% lower. GWPH is holding a Zacks Rank of #3 (Hold) right now.

The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 96, putting it in the top 38% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow GWPH in the coming trading sessions, be sure to utilize Zacks.com.


Click to get this free report

GW Pharmaceuticals PLC (GWPH): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More